Cardiol Therapeutics Stock (NASDAQ: CRDL)

Dernières nouvelles pour Cardiol Therapeutics (NASDAQ:CRDL) Stock

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

Evercore ISI Group analyst David Motemaden maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a In-Line and raises the price target from $104 to $107.

News

Price Target

Analyst Ratings

ACGL

Evercore ISI Group Maintains In-Line on Arch Capital Group, Raises Price Target to $107

Federal Reserve

Fed's Logan Says Remain Attentive To Inflation Risks From Supply Chains, Geopolitics, Port Strike; As Labor Market Has Cooled, We Face More Risk It Will Cool Beyond What Is Needed To Return Inflation To 2%

VCI Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) (Frankfurt: H0T) ("VCI Global" or the "Company"), through its subsidiary, V Gallant Sdn Bhd ("V-Gallant"), is offering end-to-end AI computing solutions to enterprises by integrating next-generation AI servers equipped with NVIDIA H200 Tensor Core GPUs and AI software such as Large Language Models (LLMs) and automated machine learning platforms. Beyond seamless integration, enterprises can enhance operational efficiency by optimizing computing power distribution, improving data flow, and task automation.

VCIG

VCI Global Unleashes Enterprise AI Solutions With V-Gallant, Leveraging NVIDIA's Computing Infrastructure

Morgan Stanley analyst James Faucette upgrades Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from Underweight to Equal-Weight and raises the price target from $20 to $37.

Upgrades

AFRM

Morgan Stanley Upgrades Affirm Holdings to Equal-Weight, Raises Price Target to $37

Fed's Logan Says US Economy 'Strong And Stable' But There Are 'Meaningful Uncertainties' Around Outlook; Spending, Economic Growth That's Stronger Than Forecast Poses Upside Risk To Inflation; Unwarranted Further Easing In Financial Conditions Could Also Push Demand Out Of Balance With Supply; 'Neutral' Fed Funds Rate Is Uncertain; Structural Economic Changes Mean It May Be Higher Than Pre-Pandemic

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital --
BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately $110 million private placement financing, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in pulmonary arterial hypertension ("PAH") and for general corporate purposes.
The private placement was led by new investor Soleus Capital, with participation from new investors including Sands Capital, Fairmount, Blackstone Multi-Asset Investing, Commodore Capital, Perceptive Advisors, ADAR1 Capital Management, BSQUARED Capital, Nantahala Capital, Stonepine Capital Management and Spruce Street Capital.
In connection with and to be effective immediately prior to the closing of this financing, two current members of the Board of Directors, Ms. Gisele Dion and Dr. Paul Grint, will resign and four new directors will join the Company's board: Roberto Bellini (former Chief Executive of BELLUS Health Inc. and current Managing Partner of BSQUARED Capital), Amit Munshi (current Chief Executive of Orna Therapeutics and former CEO of Arena Pharmaceuticals), Arvind Kush (current CFO of Candid Therapeutics and former CFO of RayzeBio) and David Canner (Partner at Soleus Capital). In addition, Mr. Bellini will serve as Independent Chairperson of the Board of Directors.
The Company is selling an aggregate of 58,310,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 21,985,000 shares of common stock, along with accompanying Series A-1 warrants to purchase an aggregate of 40,139,474 shares of common stock (or, in lieu thereof, additional pre-funded warrants) (the "Series A-1 Warrants") and accompanying Series B-1 warrants to purchase an aggregate of 73,813,529 shares of common stock (or, in lieu thereof, additional pre-funded warrants) (the "Series B-1 Warrants"). The purchase price for each share of common stock and accompanying warrants is $1.37 (provided, the purchase price for each pre-funded warrant and accompanying warrants is $1.369). The pre-funded warrants have an exercise price of $0.001 per share and are exercisable at any time after their original issuance and will not expire.&nbsp;The accompanying Series A-1 and Series B-1 Warrants will become exercisable &nbsp;at the earlier of (a) the 75th calendar day following the initial filing of the resale registration statement covering the resale of the shares of common stock issuable upon the exercise of the warrants, if the United States Securities and Exchange Commission (the "SEC") notifies the Company that it will review the resale registration statement and (b) the 5th business day after the date the Company is notified by the SEC that the resale registration statement will not be subject to further review. Each Series A-1 Warrant will be exercisable for approximately 0.5 shares of common stock and will expire 30 days following the later of (a) the date of the Company's public announcement of the safety and tolerability of IkT-001Pro for PAH and (b) the Company both obtaining stockholder approval to and filing an amendment to its charter to increase the number of authorized shares of common stock to a number of shares of common stock sufficient to allow for the full exercise of the warrants (the ‘Charter Amendment"). Each Series B-1 Warrant will be exercisable for approximately 0.92 shares of common stock, will become exercisable by an investor once all of such investor's A-1 Warrants have been exercised and will expire 30 days following the later of (a) the Company's public announcement of its Phase 2b efficacy readout for IkT-001Pro with respect to PAH and (b) the Charter Amendment. The Series A-1 Warrants have an exercise price of $1.37 per share and the Series B-1 Warrants have an exercise price of $1.49 per share.&nbsp;
The PIPE is expected to close on October 21, 2024, subject to customary closing conditions.
Jefferies is acting as the lead placement agent for the private placement. Maxim Group LLC is acting as a co-placement agent.

Offerings

Inhibikase Therapeutics Announces Pricing Of $110M Private Placement To Advance IkT-001Pro, Into A Late-Stage Trial In Pulmonary Arterial Hypertension; Aggregate Investment Of Up To ~$275M By Healthcare-Focused Investment Funds, Led By Soleus Capital

Fed's Logan Says Less Restrictive Policy Will Help Avoid Cooling Labor Market More Than Necessary; Progress On Inflation Has Been Broad-Based; Labor Market Has Cooled, Remains Healthy; Inflation, Labor Market 'Within Striking Distance' Of Fed's Goals; Recent Trends In Inflation For Housing, Other Core Services 'Encouraging,' Expect To Come Down Over Time

Barclays analyst John Coffey initiates coverage on Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight rating and announces Price Target of $120.

Initiation

FOUR

Barclays Initiates Coverage On Shift4 Payments with Overweight Rating, Announces Price Target of $120

Dallas Fed's Logan Says 'More Gradual Path' On Rate Cuts Likely Appropriate From Here; Upside Risks To Inflation Mean Fed Should Not Rush To Reduce Rates; Continue To See A Meaningful Risk Inflation Could Get Stuck Above Fed's 2% Goal; Lowering Policy Rate Gradually Would Allow Time To Judge How Restrictive Monetary Policy May Or May Not Be; Supported Fed's Decision To Begin Normalizing Policy By Cutting The Policy Rate

After an HBO documentary identified Peter Todd as Satoshi Nakamoto, the creator of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), speculation beyond the cryptocurrency community abounds about the <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41221351/elon-musks-theory-gains-ground-polymarket-odds-soar-for-nick-szabo-being-named-bitcoin-cre">veracity of the claims.</a>
What Happened: POLITICO&#8217;s Senior Finance Editor Izabella Kaminska <a href="https://x.com/izakaminska/status/1843900083873432052?s=46">argued</a> in a reaction on social media platform X on Tuesday that the immediate dismissal of Todd as a potential Satoshi candidate by the crypto community may be premature.
She points out that many who are now ridiculing the documentary were recently convinced that <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41244415/peter-todd-themed-memecoin-explodes-over-1500-after-hbo-documentary-identifies-him-as-bitc">Len Sassaman</a> would be named Satoshi, demonstrating the community&#8217;s susceptibility to social engineering.
Addressing the criticism that Todd was too young to be Satoshi, Kaminska draws a parallel to Vitalik Buterin&#8217;s creation of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) at a young age, stating, &#8220;Savants are like that. Not a credible counter criticism in my opinion.&#8221;
Todd himself took to X to deny the claim stating that "this might be crazier than before."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I&#39;m not Satoshi.
&mdash; Peter Todd (@peterktodd) <a href="https://twitter.com/peterktodd/status/1843789750983110697?ref_src=twsrc%5Etfw">October 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41242615/peter-todd-is-satoshi-nakamoto-bitcoin-core-developer-denies-hbo-documentary-claims-im-not">Peter Todd Is Satoshi Nakamoto? Bitcoin Core Developer Denies HBO Documentary Claims: &#8216;I&#8217;m Not Satoshi&#8217;</a>
Kaminska also highlighted the logic behind documentary&#8217;s argument, suggesting that Todd&#8217;s youth and lack of clout in the community could have been reasons for assuming an alias. She notes, &#8220;Even if Todd mostly wrote the paper and was the one who engaged in key development comms as Satoshi it doesn&#8217;t exclude the possibility that he also got a lot of wing support from the OGs, and the whole thing was really a group effort.&#8221;
Kaminska finds the body language in the documentary compelling and questions whether Todd or Adam Back could pass a polygraph test regarding their involvement with Satoshi&#8217;s identity.
She also points out several factors that align Todd with the Satoshi profile, including his Canadian nationality explaining Britishisms in Satoshi&#8217;s writing, his early interest in solving the &#8220;money problem,&#8221; and the mysterious scrubbing of his old CV from the internet.
While acknowledging that none of these points definitively prove Todd is Satoshi, Kaminska argues that the theory is not &#8220;laughable&#8221; and is &#8220;just as plausible as any of the other key pantheon suspect members.&#8221;
What's Next: These discussions will be central topics at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41200679/len-sassaman-is-bitcoin-creator-satoshi-nakamoto-in-hbo-documentary-polymarket-punters-see">Len Sassaman Is Bitcoin Creator Satoshi Nakamoto In HBO Documentary? Polymarket Punters See High Probability</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Peter Todd Says 'I'm Not Satoshi' But Not Everyone's Buying That: 'Just As Plausible' As The Other Theories, Says Financial Journalist

La Rosa Holdings Corp. (NASDAQ:&nbsp;LRHC) ("La Rosa" or the "Company"), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced the launch of My Agent Account version 3.0, a significant upgrade to its proprietary platform, which now includes a new module specifically designed for property management disbursements. This update is expected to improve operational efficiency for agents across the Company.
My Agent Account, La Rosa's proprietary platform, was designed to empower agents with a comprehensive suite of tools and resources. Serving as a centralized hub, it enables agents to stay connected, informed, and efficient in their daily operations. A key feature of the platform is JAEME, a real estate AI assistant designed to inspire and support agents by providing personalized content that boosts marketing, efficiency, and sales efforts. All La Rosa offices have access to My Agent Account and are required to pay a mandatory monthly or annual subscription fee per agent for it.

LRHC

La Rosa Holdings Launches My Agent Account Version 3.0 With Enhanced Property Management Disbursement Features; Expected To Enhance La Rosa's Agents' Productivity And Efficiency By 50% By Year-End

Dallas Fed's Logan: 'More Gradual Path' On Rate Cuts Likely Appropriate From Here; Upside Risks To Inflation Mean Fed Should Not Rush To Reduce Rates; Continue To See A Meaningful Risk Inflation Could Get Stuck Above Fed's 2% Goal; Lowering Policy Rate Gradually Would Allow Time To Judge How Restrictive Monetary Policy May Or May Not Be; Normalizing Policy Gradually Also Allows Fed To 'Best Balance' Labor Market Risks; Policy Not 'Preset,' Fed Must Remain Nimble

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities.
Details of the presentation are listed below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td><a href="https://cm.eortc.org/cmPortal/Searchable/ena2024/config/Normal#!sessiondetails/0000110740_0">Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations</a></td>
</tr>
<tr>
<td>Abstract Number:</td>
<td>59</td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular Targeted Agents</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024</td>
</tr>
</tbody>
</table>
</figure>

Biotech

General

CYCC

CYCCP

Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-
SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=k-ZoVyGjmR4fPa-ggsCwX0d3bU62O3KFvndaNaOg7r8TG4XvHKKg7sIHfXFbcECW1l1J82s3n4TSKRk51b_s9PvNGR3xpBs63hjKZhN52gpkVh9TDIoXLu886sMbAm3HHRUf6fjKM4e4izUwBmSMdPDDJa50xXk81CFEilZzubaAkSYGpM4f3YP6bI_HfvhYU2bRb0N7e5XuAd1B8mxS0qELCIGmfz1g1fPd2q1QcYQvy8YPyxFIswBwgzpIkuviB6A-If787YSkMC0tuXIcGw==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that it has initiated its rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA), seeking full approval for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.

CAPR

Capricor Therapeutics Announces Initiation Of Rolling Submission Of BLA With U.S. FDA For Deramiocel For The Treatment Of Duchenne Muscular Dystrophy

Coca-Cola's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) short percent of float has risen 3.26% since its last report. The company recently reported that it has 40.65 million shares sold short, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Coca-Cola Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728479723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Coca-Cola has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Coca-Cola's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Coca-Cola's peer group average for short interest as a percentage of float is 7.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Coca-Cola's Recent Short Interest

Fortinet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NYSE">FTNT</a>) short percent of float has risen 5.99% since its last report. The company recently reported that it has 14.52 million shares sold short, which is 2.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fortinet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728479718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fortinet has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fortinet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fortinet's peer group average for short interest as a percentage of float is 5.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FTNT

How Is The Market Feeling About Fortinet?

Dave Ramsey recently hosted an <a href="https://www.youtube.com/watch?v=UD0ZOogTW5w&amp;t=0s">engaging conversation</a> with former President Donald Trump, focusing on pressing financial concerns. Ramsey, known for his straightforward personal finance advice, kicked off the interview by reminding listeners that his show is about money, not politics.&nbsp;
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>
However, with the upcoming election in mind, he said, &#8220;I invited both candidates to discuss ideas and what's going to happen.&#8221; While <a href="https://www.benzinga.com/real-estate/24/09/40969108/harris-partners-with-big-money-backers-to-boost-americas-housing-supply-will-it-be-enough-to-solve-t">Vice President Kamala Harris&#8217;s</a> team had yet to respond to Ramsey&#8217;s invitation, Trump quickly sat down to share his thoughts.
Ramsey&#8217;s listeners are more worried about skyrocketing costs than politics and he didn't hold back when bringing up their concerns. "People aren't as bothered by all the political drama," he told Trump. "They're focused on $8 eggs, $5 gas, 7% interest rates and houses they can't afford. Wages aren't keeping up and inflation's out of control."
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
In response, Trump connected inflation to energy prices. &#8220;The first thing I'd do to lower costs is drill. We've got to drill, baby, drill,&#8221; he said confidently, promising to ramp up domestic oil production if he wins in 2024.&nbsp;
According to Trump, this would bring down oil prices and help ease inflation. &#8220;Lower energy prices take the pressure off the economy and reduce inflation overall,&#8221; he added.
However, the Bureau of Labor Statistics reported that the average price of eggs had dropped to $3.20 per dozen by August. The national average price for gas is currently $3.177 per gallon, based on data from AAA. Mortgage rates spiked to 8% in 2023 and have since eased. As of Sept. 26, Freddie Mac reported that the average rate for a 30-year fixed mortgage was down to 6.08%.&nbsp;
Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
The combination of the pandemic and global events like the Russia-Ukraine conflict hasn't helped either. Meanwhile, Harris has defended the Biden administration's efforts, pointing out that domestic oil production is at an all-time high. She's also a strong advocate for investing in renewable energy to reduce dependency on foreign oil.
The conversation then turned to Social Security, an issue many Americans are concerned about. Experts have warned that the Social Security Trust Fund could run dry in just eight years. When asked about solutions, Trump vowed to protect the program without raising the retirement age.&nbsp;
"We need to keep it solid," he emphasized, although he controversially claimed that migrants receiving public benefits were part of the problem – a point fact-checkers have repeatedly refuted.
See Also: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>
<a href="https://www.benzinga.com/startups/24/09/40969537/trump-familys-crypto-venture-revealed-new-buying-rules-who-can-invest-and-what-it-means-for-early-ad">Trump </a>reiterated his familiar stance on taxes: lower corporate taxes and introduce tariffs on foreign goods to boost American manufacturing. "You make your product here, you pay 15% and I'll slap tariffs on countries that try to undercut us," he stated. But experts aren't so sure.&nbsp;
Economists estimate that Trump's tax cuts from 2017 could add nearly $2 trillion to the national deficit by 2028. Tariffs, they say, might also raise consumer prices, something Harris's team frequently points out.
See Also: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
One of the lighter moments in the interview came when Ramsey asked Trump about parenting. &#8220;How do you raise great kids?&#8221; he asked. Trump's answer was simple: &#8220;I always told mine, no drugs, no alcohol, no cigarettes.&#8221;&nbsp;
He also opened up about how his older brother's battle with alcoholism influenced his own decision to never drink. His advice for teaching kids about hard work? &#8220;They've got to enjoy what they do. If they don't love it, it won't work.&#8221;
Read Next:
<ul>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Personal Finance

Trump and Dave Ramsey Break Down '$8 Eggs, $5 Gas and 7% Interest Rates' – Can Anyone Afford a House in This Economy?

RTX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) short percent of float has fallen 8.65% since its last report. The company recently reported that it has 12.58 million shares sold short, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>RTX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728479713_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RTX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing RTX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, RTX's peer group average for short interest as a percentage of float is 2.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into RTX's Recent Short Interest

<ul>
<li>NVDA</li>
<li>BABA</li>
<li>LOT</li>
<li>TSLA</li>
<li>WAY</li>
<li>YINN</li>
<li>MADE</li>
<li>MSTR</li>
<li>MSFT</li>
<li>GOOG</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BABA

GOOG

MADE

MSFT

MSTR

NVDA

TSLA

YINN

Top 10 Trending Stocks On WallStreetBets As Of October 9, 2024 (Via Swaggy Stocks)

WIIM

OGEN

Oragenics shares are trading higher after the company provided a corporate update on its 2024 progress including developments of ONP-002, its lead candidate for concussions.

Cardiol Therapeutics (CRDL) has received a new Buy rating, initiated by Roth MKM analyst, Jason Wittes. Jason Wittes has given his Buy rating due t...

Buy Rating on Cardiol Therapeutics: Promising CardioRx Pipeline and Positive Clinical Trials

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. successfully held its 2024 Annual General and Special Meeting whe...

Cardiol Therapeutics Shareholders Approve Resolutions

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. has received consent from Borden Ladner Gervais LLP for the use o...

Cardiol Therapeutics Gains Key Legal Consent

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. reported a decrease in total assets from CAD 36.7 million as of D...

Cardiol Therapeutics Inc.: Financial Update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cardiol Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crdl-stock-quote/">CRDL</a>) just reported results for the second quarter of 2024.<ul><li>Cardiol Therapeutics reported earnings per share of -7.3 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/crdl-stock-earnings-cardiol-therapeutics-for-q2-of-2024/">CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024

Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully completed the MAvERIC Phase II study for recurrent pe...

Cardiol Therapeutics Advances Heart Disease Treatment

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial, t...

Cardiol Therapeutics' Landmark Enrollment for Heart Drug Trial

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc., a clinical-stage company specializing in heart disease treatment...

Cardiol Therapeutics Announces Public Share Offering

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics, a clinical-stage life sciences company, has announced the pricing of ...

Cardiol Therapeutics Sets Common Share Offering Price

CRDL

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Press Releases

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

"Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…"

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

KAVL

PEGY

PRSO

SMFL

TNON

TSX:CRDL

UMAC

Roth MKM

HC Wainwright & Co.

Canaccord Genuity

Cantor Fitzgerald

Cardiol Therapeutics shares are trading lower after the company announced a $13.5 million public offering of 8,437,500 common shares priced at $1.60 per unit.

Comments

Cardiol Therapeutics

Actualités

Dernières nouvelles pour Cardiol Therapeutics (NASDAQ:CRDL) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL